Microlyte® Matrix Featured in Clinical Research Presented at National Wound Healing Conference
MADISON, WI, OCTOBER 12, 2019
Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that clinical results documenting the use of its flagship product, Microlyte® Matrix resorbable antimicrobial wound matrix, will be presented at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV on October 13, 2019. SAWC is the nation’s largest interdisciplinary wound care forum.
SHARE THIS ARTICLE
The poster presentations, delivered by several of Imbed’s clinical collaborators, will highlight results in a variety of complex, chronic wounds and surgical applications. The clinical case series were conducted independently at Mount Sinai Hospital (New York), Temple University School of Podiatric Medicine (Philadelphia), the Institute for Advanced Wound Care (Montgomery, AL), and St. Vincent Health (Billings, MT) and typically evaluated wound closure after application of Microlyte® Matrix to leg ulcers, surgical wounds in diabetic patients, and various chronic colonized wounds. The cases conducted at Mount Sinai involved the use of Microlyte® Matrix under a biologic graft material.
“This set of research posters is the latest demonstration of what Microlyte® Matrix can do in aiding healing in both acute and chronic wounds. We are grateful to the world-class clinical partners that have embrace this new an exciting product in the treatment of their patients,” said Jeff Dalsin, PhD, Imbed’s Vice President of Products. “We hear every day how Microlyte® Matrix is changing people’s lives. That makes our work exceptionally gratifying.”
SAWC poster presentations featuring Microlyte® Matrix during the SAWC Poster Gala from 5:15 to 6:15pm on October 13 will include:
The poster maybe reviewed throughout the day on Sunday, October 13 in the Julius 12 Ballroom inside Caesar’s Palace.
Microlyte® Matrix is primarily composed of an ultrathin, resorbable polymeric film, which means it never needs to be removed from the wound bed. Microlyte® Matrix is also fully synthetic, so there is no risk of disease transmission from animal based-components and it has a long shelf-life under ambient conditions (2 years or more). Microlyte® Matrix is cleared for application in acute wounds such as lacerations, skin tears, abrasions, surgical wounds (e.g., donor and graft sites, incisions), partial thickness first- and second-degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers. The product may be applied daily or up to every 3 days, depending on the wound and the healing progression. The duration of the treatment depends on wound type and healing conditions.
About Imbed Biosciences, Inc.
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented Microlyte® Matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.www.imbedbio.com
SHARE THIS ARTICLE